BPG is committed to discovery and dissemination of knowledge
Review
©The Author(s) 2025.
World J Gastroenterol. Sep 28, 2025; 31(36): 109143
Published online Sep 28, 2025. doi: 10.3748/wjg.v31.i36.109143
Table 8 Available randomised studies on the dietary emulsifier restriction and their effect
Ref.
Type of study
Population characteristics, n
Outcome parameters
Key findings
Bhattacharyya et al[125], 2017RCTCases (n = 5): UC in remission on 100mg carrageenan-containing capsule; Controls (n = 7): UC in remission on placebo capsulesRelapse in two groups at different time points (3, 6, 9, and 12 months); Relapse is defined as an increase of two (or more) points on the SCCAIRelapses were higher with the carrageenan diet (P = 0.046); Increase in interleukin-6 (P = 0.02) and fecal calprotectin (P = 0.06) in carrageenan diet group
Chassaing et al[126], 2022RCTCases (n = 7): Diet enriched with 15 g/day of CMC; Controls (n = 9): Emulsifier-free dietsMetabolic impact in healthy volunteers: Effect on human gut microbiota composition and gene expressionCMC reduced microbiota richness with a decrease in evenness and Shannon indices; CMC consumption affected the fecal metabolome with depletion of short-chain fatty acids and free amino acids
Fitzpatrick et al[127], 2025RCTHED (n = 12) vs LED (n = 12) was provided for 4 weeks in patients with CDThe emulsifier content did not influence disease activity in CD
Bancil et al[128], 2025Multicentric RCTLED (n = 75) vs LED plus emulsifier re-supplementation (Controls, n = 79) was provided for 8 weeks in active CDPrimary endpoint: Proportion of patients achieving CDAI response (≥ 70 reduction) at 8 weeks; Secondary endpoint: CDAI remission and fecal calprotectinCDAI response was achieved in 39 (49.4%) on LED vs 23 (30.7%) in the control group (P = 0.019); Patients on LED are more than twice as likely to experience CDAI remission (adjusted RR: 2.1, 95%CI: 1.0-4.42) and > 50% reduction in FCP (adjusted RR: 2.9, 95%CI: 1.1-8.0)


Write to the Help Desk